NCT00002249View on ClinicalTrials.gov

A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Levofloxacin

Trial Locations (1)

088690602

R W Johnson Pharmaceutical Research Institute, Raritan

All Listed Sponsors

lead

R W Johnson Pharmaceutical Research Institute

INDUSTRY

NCT00002249 - A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection | Biotech Hunter | Biotech Hunter